JP2006505562A - 持続放出組成物の放出プロフィールの調節方法 - Google Patents

持続放出組成物の放出プロフィールの調節方法 Download PDF

Info

Publication number
JP2006505562A
JP2006505562A JP2004544829A JP2004544829A JP2006505562A JP 2006505562 A JP2006505562 A JP 2006505562A JP 2004544829 A JP2004544829 A JP 2004544829A JP 2004544829 A JP2004544829 A JP 2004544829A JP 2006505562 A JP2006505562 A JP 2006505562A
Authority
JP
Japan
Prior art keywords
microparticles
triamcinolone
sustained release
biologically active
epo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004544829A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006505562A5 (enExample
Inventor
ダシュ，ジェームズ，アール．
ライリー，ガリー，エム．，アイ．
バーク，ポール，エイ．
ステイツ−アバディ，スーザン，エイ．
ゼール，スティーブン，イー．
Original Assignee
アルカーメス コントロールド セラピューティクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルカーメス コントロールド セラピューティクス，インコーポレイテッド filed Critical アルカーメス コントロールド セラピューティクス，インコーポレイテッド
Publication of JP2006505562A publication Critical patent/JP2006505562A/ja
Publication of JP2006505562A5 publication Critical patent/JP2006505562A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2004544829A 2002-10-17 2003-10-08 持続放出組成物の放出プロフィールの調節方法 Pending JP2006505562A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41943002P 2002-10-17 2002-10-17
PCT/US2003/032017 WO2004034975A2 (en) 2002-10-17 2003-10-08 Sustained release profile modification

Publications (2)

Publication Number Publication Date
JP2006505562A true JP2006505562A (ja) 2006-02-16
JP2006505562A5 JP2006505562A5 (enExample) 2006-11-16

Family

ID=32108081

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004544829A Pending JP2006505562A (ja) 2002-10-17 2003-10-08 持続放出組成物の放出プロフィールの調節方法

Country Status (6)

Country Link
US (2) US20040121009A1 (enExample)
EP (1) EP1567127A4 (enExample)
JP (1) JP2006505562A (enExample)
AU (1) AU2003284028B2 (enExample)
CA (1) CA2501298A1 (enExample)
WO (1) WO2004034975A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6824822B2 (en) * 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US7456254B2 (en) * 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
HRP20110831T1 (hr) * 2004-04-15 2012-01-31 Alkermes Pharma Ireland Limited Oblik za produljeno oslobađanje na bazi polimera
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
HRP20150186T1 (hr) * 2005-08-19 2015-05-22 Amylin Pharmaceuticals, Llc. Eksendin za lijeäśenje dijabetesa i smanjenje tjelesne težine
MX2009001114A (es) 2006-08-09 2009-02-10 Intarcia Therapeutics Inc Sistemas de suministro osmotico y ensambles de piston.
GR1005808B (el) * 2006-11-27 2008-02-06 Bionature E.A. Limited Επιταση της δρασεως της ερυθροποιητινης με αγωνιστες των μεμβρανικων στεροειδων υποδοχεων
EP2131815A4 (en) * 2007-03-22 2012-11-07 Alkermes Inc coacervation
CN104000779A (zh) 2007-04-23 2014-08-27 精达制药公司 促胰岛素释放肽的混悬制剂及其应用
US8470360B2 (en) * 2008-04-18 2013-06-25 Warsaw Orthopedic, Inc. Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US20090263456A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Methods and Compositions for Reducing Preventing and Treating Adhesives
WO2009143285A2 (en) * 2008-05-21 2009-11-26 Amylin Pharmaceuticals, Inc. Exendins to lower cholestrol and triglycerides
DK2462246T3 (da) 2009-09-28 2017-11-06 Intarcia Therapeutics Inc Hurtig etablering og/eller afslutning af væsentlig steady-state-lægemiddelafgivelse
UA111162C2 (uk) 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP2934562A1 (en) * 2012-08-14 2015-10-28 Wockhardt Limited Pharmaceutical microparticulate compositions of polypeptides
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
MA53353A (fr) 2016-05-16 2021-06-09 Intarcia Therapeutics Inc Polypeptides sélectifs pour le récepteur du glucagon et méthodes pour leur utilisation
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08503695A (ja) * 1992-09-10 1996-04-23 チルドレンズ メディカル センター コーポレイション 局所麻酔剤の持続性送達のための生分解性ポリマーマトリックス
JPH11504634A (ja) * 1995-05-01 1999-04-27 チルドレンズ メディカル センター コーポレイション 局所麻酔薬とグルココルチコイドとの組み合わせによる延長された神経遮断
JPH11506450A (ja) * 1995-06-02 1999-06-08 オキュレックス ファーマシューティカルズ，インコーポレイティド 親水性及び疎水性薬剤の組合せによる薬剤の制御放出のための改良処方物
JP2000511941A (ja) * 1997-07-02 2000-09-12 ユーロ−セルティーク エス．エイ． 関節間隙および身体間隙における持効性麻酔
WO2001043762A2 (en) * 1999-12-16 2001-06-21 Eli Lilly And Company Polypeptide compositions with improved stability
WO2001087267A1 (en) * 2000-02-28 2001-11-22 Gel-Del Technologies, Inc. Protein matrix materials, devices and methods of making and using thereof
JP2002520120A (ja) * 1998-07-17 2002-07-09 スカイファーマ インコーポレーテッド 封入物質の制御放出のための生分解性組成物
JP2002234833A (ja) * 2001-02-08 2002-08-23 Taiyo Yakuhin Kogyo Kk 徐放型マイクロカプセルの製造法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4530840A (en) * 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4542025A (en) * 1982-07-29 1985-09-17 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US6024983A (en) * 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US5019400A (en) * 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5707644A (en) * 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5922340A (en) * 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
AU677115B2 (en) * 1994-12-19 1997-04-10 University Of Miami Biodegradable injectable drug delivery polymer
GB9513118D0 (en) * 1995-06-28 1995-08-30 Merck Sharp & Dohme Therapeutic agents
CA2192782C (en) * 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
CN1126537C (zh) * 1996-05-23 2003-11-05 株式会社三养社 可局部给药,可生物降解和持续释放的用于治疗牙周炎的药物组合物及其制备方法
US6046187A (en) * 1996-09-16 2000-04-04 Children's Medical Center Corporation Formulations and methods for providing prolonged local anesthesia
US6203813B1 (en) * 1997-01-13 2001-03-20 Lance L. Gooberman Pharmaceutical delivery device and method of preparation therefor
AU2003286472A1 (en) * 2002-10-17 2004-05-04 Alkermes Controlled Therapeutics, Inc. Ii Microencapsulation and sustained release of biologically active polypeptides

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08503695A (ja) * 1992-09-10 1996-04-23 チルドレンズ メディカル センター コーポレイション 局所麻酔剤の持続性送達のための生分解性ポリマーマトリックス
JPH11504634A (ja) * 1995-05-01 1999-04-27 チルドレンズ メディカル センター コーポレイション 局所麻酔薬とグルココルチコイドとの組み合わせによる延長された神経遮断
JPH11506450A (ja) * 1995-06-02 1999-06-08 オキュレックス ファーマシューティカルズ，インコーポレイティド 親水性及び疎水性薬剤の組合せによる薬剤の制御放出のための改良処方物
JP2000511941A (ja) * 1997-07-02 2000-09-12 ユーロ−セルティーク エス．エイ． 関節間隙および身体間隙における持効性麻酔
JP2002520120A (ja) * 1998-07-17 2002-07-09 スカイファーマ インコーポレーテッド 封入物質の制御放出のための生分解性組成物
WO2001043762A2 (en) * 1999-12-16 2001-06-21 Eli Lilly And Company Polypeptide compositions with improved stability
WO2001087267A1 (en) * 2000-02-28 2001-11-22 Gel-Del Technologies, Inc. Protein matrix materials, devices and methods of making and using thereof
JP2002234833A (ja) * 2001-02-08 2002-08-23 Taiyo Yakuhin Kogyo Kk 徐放型マイクロカプセルの製造法

Also Published As

Publication number Publication date
CA2501298A1 (en) 2004-04-29
US20040121009A1 (en) 2004-06-24
AU2003284028B2 (en) 2007-05-10
WO2004034975A2 (en) 2004-04-29
AU2003284028A1 (en) 2004-05-04
EP1567127A2 (en) 2005-08-31
US20080057131A1 (en) 2008-03-06
EP1567127A4 (en) 2007-02-21
WO2004034975A3 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
US20080057131A1 (en) Method of modifying the release profile of sustained release compositions
CA2560874C (en) Poly (lactide-co-glycolide)-based sustained release microcapsules comprising a polypeptide and a sugar
US8877252B2 (en) Polymer-based sustained release device
WO2004035754A2 (en) Microencapsulation and sustained release of biologically active polypeptides
US20060110423A1 (en) Polymer-based sustained release device
AU2006235955A1 (en) Poly (lactide-co-glycolide)-based sustained release microcapsules comprising a polypeptide and a sugar
HK1139320A (en) Poly(lactide-co-glycolide)-based sustained release microcapsules comprising a polypeptide and a sugar

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060927

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060927

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20061113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20061113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100428

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100511

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100607

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100614

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101025